Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma

D. Michael Rose, William C. Chapman, Andrew T. Brockenbrough, J. Kelly Wright, Amy T. Rose, Steven Meranze, Murray Mazer, Taylor Blair, Charles Blanke, J. P. Debelak, C. Wright Pinson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) in Western populations has historically been associated with poor survival. METHOD: In this study, we conducted a 7-year retrospective analysis of patients with HCC undergoing transcatheter arterial chemoembolization (TACE) at our institution and examined demographics, outcomes, and complications. RESULTS: During the period of study, 39 patients (25 male [64%], mean age 58 [range 17 to 86]) underwent a total of 78 chemoembolization treatments. During the same time period, an additional 31 patients received supportive care only. The majority of patients had late stage disease (American Joint Committee on Cancer stage III, IVa, or IVb) with no statistical difference noted between the two groups (P = 0.2). However, patients receiving supportive care only had significantly worse hepatic dysfunction by Child's classification (P = 0.005). Twenty-nine patients (74%) had documented cirrhosis, with hepatitis C being the most common cause in 11 of 29 (38%). In patients undergoing TACE, overall actuarial survival was 35%, 20%, and 11% at 1, 2, and 3 years with a median survival of 9.2 months, significantly improved over the group receiving supportive care only (P <0.0001). Median survival for the group receiving supportive care was less than 3 months. Neither age nor stage had a significant impact on survival. The most common complications of TACE included transient nausea, abdominal pain, vomiting, and fever. CONCLUSIONS: TACE iS a safe and effective therapeutic option for selected patients with HCC not amenable to surgical intervention.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalAmerican Journal of Surgery
Volume177
Issue number5
DOIs
StatePublished - May 1999
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Survival
Therapeutics
Joint Diseases
Hepatitis C
Nausea
Abdominal Pain
Vomiting
Fibrosis
Fever
Demography
Liver
Population
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Rose, D. M., Chapman, W. C., Brockenbrough, A. T., Wright, J. K., Rose, A. T., Meranze, S., ... Pinson, C. W. (1999). Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. American Journal of Surgery, 177(5), 405-410. https://doi.org/10.1016/S0002-9610(99)00069-0

Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. / Rose, D. Michael; Chapman, William C.; Brockenbrough, Andrew T.; Wright, J. Kelly; Rose, Amy T.; Meranze, Steven; Mazer, Murray; Blair, Taylor; Blanke, Charles; Debelak, J. P.; Pinson, C. Wright.

In: American Journal of Surgery, Vol. 177, No. 5, 05.1999, p. 405-410.

Research output: Contribution to journalArticle

Rose, DM, Chapman, WC, Brockenbrough, AT, Wright, JK, Rose, AT, Meranze, S, Mazer, M, Blair, T, Blanke, C, Debelak, JP & Pinson, CW 1999, 'Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma', American Journal of Surgery, vol. 177, no. 5, pp. 405-410. https://doi.org/10.1016/S0002-9610(99)00069-0
Rose, D. Michael ; Chapman, William C. ; Brockenbrough, Andrew T. ; Wright, J. Kelly ; Rose, Amy T. ; Meranze, Steven ; Mazer, Murray ; Blair, Taylor ; Blanke, Charles ; Debelak, J. P. ; Pinson, C. Wright. / Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. In: American Journal of Surgery. 1999 ; Vol. 177, No. 5. pp. 405-410.
@article{ecf9009025b94991b1c1de3e196f6910,
title = "Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma",
abstract = "BACKGROUND: Hepatocellular carcinoma (HCC) in Western populations has historically been associated with poor survival. METHOD: In this study, we conducted a 7-year retrospective analysis of patients with HCC undergoing transcatheter arterial chemoembolization (TACE) at our institution and examined demographics, outcomes, and complications. RESULTS: During the period of study, 39 patients (25 male [64{\%}], mean age 58 [range 17 to 86]) underwent a total of 78 chemoembolization treatments. During the same time period, an additional 31 patients received supportive care only. The majority of patients had late stage disease (American Joint Committee on Cancer stage III, IVa, or IVb) with no statistical difference noted between the two groups (P = 0.2). However, patients receiving supportive care only had significantly worse hepatic dysfunction by Child's classification (P = 0.005). Twenty-nine patients (74{\%}) had documented cirrhosis, with hepatitis C being the most common cause in 11 of 29 (38{\%}). In patients undergoing TACE, overall actuarial survival was 35{\%}, 20{\%}, and 11{\%} at 1, 2, and 3 years with a median survival of 9.2 months, significantly improved over the group receiving supportive care only (P <0.0001). Median survival for the group receiving supportive care was less than 3 months. Neither age nor stage had a significant impact on survival. The most common complications of TACE included transient nausea, abdominal pain, vomiting, and fever. CONCLUSIONS: TACE iS a safe and effective therapeutic option for selected patients with HCC not amenable to surgical intervention.",
author = "Rose, {D. Michael} and Chapman, {William C.} and Brockenbrough, {Andrew T.} and Wright, {J. Kelly} and Rose, {Amy T.} and Steven Meranze and Murray Mazer and Taylor Blair and Charles Blanke and Debelak, {J. P.} and Pinson, {C. Wright}",
year = "1999",
month = "5",
doi = "10.1016/S0002-9610(99)00069-0",
language = "English (US)",
volume = "177",
pages = "405--410",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma

AU - Rose, D. Michael

AU - Chapman, William C.

AU - Brockenbrough, Andrew T.

AU - Wright, J. Kelly

AU - Rose, Amy T.

AU - Meranze, Steven

AU - Mazer, Murray

AU - Blair, Taylor

AU - Blanke, Charles

AU - Debelak, J. P.

AU - Pinson, C. Wright

PY - 1999/5

Y1 - 1999/5

N2 - BACKGROUND: Hepatocellular carcinoma (HCC) in Western populations has historically been associated with poor survival. METHOD: In this study, we conducted a 7-year retrospective analysis of patients with HCC undergoing transcatheter arterial chemoembolization (TACE) at our institution and examined demographics, outcomes, and complications. RESULTS: During the period of study, 39 patients (25 male [64%], mean age 58 [range 17 to 86]) underwent a total of 78 chemoembolization treatments. During the same time period, an additional 31 patients received supportive care only. The majority of patients had late stage disease (American Joint Committee on Cancer stage III, IVa, or IVb) with no statistical difference noted between the two groups (P = 0.2). However, patients receiving supportive care only had significantly worse hepatic dysfunction by Child's classification (P = 0.005). Twenty-nine patients (74%) had documented cirrhosis, with hepatitis C being the most common cause in 11 of 29 (38%). In patients undergoing TACE, overall actuarial survival was 35%, 20%, and 11% at 1, 2, and 3 years with a median survival of 9.2 months, significantly improved over the group receiving supportive care only (P <0.0001). Median survival for the group receiving supportive care was less than 3 months. Neither age nor stage had a significant impact on survival. The most common complications of TACE included transient nausea, abdominal pain, vomiting, and fever. CONCLUSIONS: TACE iS a safe and effective therapeutic option for selected patients with HCC not amenable to surgical intervention.

AB - BACKGROUND: Hepatocellular carcinoma (HCC) in Western populations has historically been associated with poor survival. METHOD: In this study, we conducted a 7-year retrospective analysis of patients with HCC undergoing transcatheter arterial chemoembolization (TACE) at our institution and examined demographics, outcomes, and complications. RESULTS: During the period of study, 39 patients (25 male [64%], mean age 58 [range 17 to 86]) underwent a total of 78 chemoembolization treatments. During the same time period, an additional 31 patients received supportive care only. The majority of patients had late stage disease (American Joint Committee on Cancer stage III, IVa, or IVb) with no statistical difference noted between the two groups (P = 0.2). However, patients receiving supportive care only had significantly worse hepatic dysfunction by Child's classification (P = 0.005). Twenty-nine patients (74%) had documented cirrhosis, with hepatitis C being the most common cause in 11 of 29 (38%). In patients undergoing TACE, overall actuarial survival was 35%, 20%, and 11% at 1, 2, and 3 years with a median survival of 9.2 months, significantly improved over the group receiving supportive care only (P <0.0001). Median survival for the group receiving supportive care was less than 3 months. Neither age nor stage had a significant impact on survival. The most common complications of TACE included transient nausea, abdominal pain, vomiting, and fever. CONCLUSIONS: TACE iS a safe and effective therapeutic option for selected patients with HCC not amenable to surgical intervention.

UR - http://www.scopus.com/inward/record.url?scp=0033136957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033136957&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(99)00069-0

DO - 10.1016/S0002-9610(99)00069-0

M3 - Article

C2 - 10365881

AN - SCOPUS:0033136957

VL - 177

SP - 405

EP - 410

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5

ER -